# JT001 (VV116) for the Early Treatment of COVID-19

> **NCT05242042** · PHASE2,PHASE3 · TERMINATED · sponsor: **Shanghai JunTop Biosciences Co., LTD** · enrollment: 381 (actual)

## Conditions studied

- Mild to Moderate COVID-19

## Interventions

- **DRUG:** JT001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05242042
- **Lead sponsor:** Shanghai JunTop Biosciences Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-28
- **Primary completion:** 2023-03-23
- **Final completion:** 2023-03-23
- **Target enrollment:** 381 (ACTUAL)
- **Why stopped:** Based on the current number of COVID-19 cases and the approval of COVID-19 treatment drugs , the research team is facing great challenges, and it is decided to terminate this study
- **Last updated:** 2023-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05242042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05242042, "JT001 (VV116) for the Early Treatment of COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05242042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*